Global Leading Market Research Publisher QYResearch announces the release of its latest report “Diagnostic Radionuclide Drug Conjugates (RDCs) – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″.
Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart):
https://www.qyresearch.com/reports/4796609/diagnostic-radionuclide-drug-conjugates–rdcs
To Nuclear Medicine Executives, Oncology Diagnostic Developers, and Precision Medicine Investors:
If your organization develops diagnostic imaging agents for oncology, cardiology, or neurology, you face a persistent challenge: achieving molecular-level specificity to detect disease at early stages, stage accurately, and monitor treatment response. Conventional imaging agents (CT, MRI, ultrasound contrast) provide anatomical information but lack molecular specificity. The solution lies in diagnostic radionuclide drug conjugates (RDCs) —a type of innovative drug that delivers radionuclides precisely to the lesion site through targeted ligands (antibodies, peptides, and small molecules) to achieve early diagnosis and precise staging of disease. According to QYResearch’s newly released market forecast, the global diagnostic radionuclide drug conjugates (RDCs) market was valued at US$4,722 million in 2024 and is projected to reach US$10,117 million by 2031, growing at a compound annual growth rate (CAGR) of 11.5 percent during the 2025-2031 forecast period. This exceptional growth reflects the rapid development of targeted nuclear medicine, the expanding use of PET and SPECT imaging, and the increasing adoption of theranostic approaches (diagnostic RDC paired with therapeutic RDC).
1. Product Definition: Targeted Molecular Imaging Using Radionuclide Conjugates
Radionuclide drug conjugates (RDCs) are a new type of diagnostic and therapeutic drug that combines the advantages of precise targeting and powerful detection. Nuclear medicine/radiopharmaceuticals refer to radioactive isotope preparations or a special type of medical drugs labeled with radioactive isotopes. Unlike tumor radiotherapy (external beam radiation delivered from outside the body), nuclear medicine radiates from inside out at the site that needs to be treated. When the same radiation dose is given, nuclear medicine can target the target site more directly. RDC combines radionuclides with ligands (such as antibodies, peptides, small molecules, etc.) through linkers and chelators. After the targeted carrier recognizes the tumor cells, it transports the carried nuclides to the location of the target cells, achieving early and specific diagnosis of the disease at the molecular level.
Diagnostic RDCs are designed for imaging applications. They use radionuclides that emit gamma rays (for SPECT imaging) or positrons (for PET imaging), such as technetium-99m (⁹⁹ᵐTc), gallium-68 (⁶⁸Ga), fluorine-18 (¹⁸F), copper-64 (⁶⁴Cu), and zirconium-89 (⁸⁹Zr). These radionuclides have short half-lives (minutes to hours), allowing imaging soon after administration with minimal radiation exposure to patients.
The market is segmented by ligand type into antibody-conjugated nuclear medicines (ARC) (using monoclonal antibodies as targeting ligands; large size (150 kDa), longer circulation time, higher specificity; suitable for targets with high antigen expression), peptide-conjugated nuclear medicines (PRC) (using peptides (e.g., somatostatin analogs) as targeting ligands; small size (1-5 kDa), rapid tumor penetration, rapid clearance; suitable for neuroendocrine tumors, prostate cancer), and small molecule conjugated nuclear medicines (SMRC) (using small molecules (e.g., PSMA inhibitors, FDG) as targeting ligands; very small size (<1 kDa), rapid uptake, rapid clearance; suitable for prostate cancer (PSMA), glucose metabolism (FDG)). Peptide-conjugated and small molecule-conjugated RDCs currently represent the largest segments (each approximately 35-40 percent of revenue), driven by their favorable pharmacokinetics (rapid tumor uptake, rapid background clearance enabling high-contrast imaging within hours). Antibody-conjugated RDCs have longer circulation times (requiring imaging 24-72 hours post-injection) but offer higher specificity.
By application, the market serves cardiovascular (myocardial perfusion imaging, cardiac sympathetic innervation imaging, atherosclerosis imaging), glioma (brain tumor imaging, amino acid transport imaging), neuroendocrine tumors (somatostatin receptor imaging using ⁶⁸Ga-DOTATATE, the most established peptide RDC application), breast cancer, pancreatic cancer, lung cancer, prostate cancer (PSMA-targeted imaging using ⁶⁸Ga-PSMA-11, ¹⁸F-DCFPyL), liver cancer, and others. Neuroendocrine tumors and prostate cancer are the largest application segments (each approximately 20-25 percent of revenue), driven by well-established peptide-based (somatostatin analogs) and small molecule-based (PSMA inhibitors) RDCs.
2. Key Advantages of RDCs Over Antibody-Drug Conjugates (ADCs)
Compared to antibody-drug conjugates (ADCs), RDCs have several significant advantages that drive their adoption in diagnostic imaging:
A. More Ligand Forms
RDC has more ligand forms than ADC, which can be antibodies, peptides, and small molecules, selected according to the characteristic targets of different tumor cells. Peptides or small molecules as ligands are much smaller in size than ADCs (antibodies are ~150 kDa; peptides are 1-5 kDa; small molecules <1 kDa), making it easier to penetrate into the internal tissue of the tumor. At the same time, RDC is highly concentrated within a range of several times the diameter of the cancer cell, thereby minimizing damage to surrounding normal tissue.
B. No Endocytosis Required
ADC needs to enter the cell through endocytosis and release the biologically active payload after lysosomal degradation, thereby inducing tumor cell apoptosis. In contrast, RDC does not need to enter the tumor cell or break the linker to release the payload; instead, it uses the radiation generated by the radionuclide of RDC during decay to kill the target cell, improving the stability and safety of RDC drugs in the body. For diagnostic RDCs, this means the radionuclide stays attached to the targeting ligand, which remains on the cell surface or is internalized, but radiation emission does not require release of a payload.
C. Better Resistance to Drug Resistance
RDC has better resistance to drug resistance. As long as the target cell is within the radiation radius (typically 0.1-10 mm depending on the radionuclide’s particle energy), even if there is no corresponding antigen (for diagnostic RDCs, this means imaging is less dependent on uniform target expression), RDC can play an indirect diagnostic or therapeutic role. This is particularly important for tumors with heterogeneous target expression.
D. Theranostic Integration
RDC simplifies the early diagnosis, treatment, and postoperative evaluation process of cancer. The same ligand can be connected to radionuclides used for disease diagnosis and treatment, respectively, facilitating the integration of diagnosis and treatment (theranostics). For example, the same somatostatin analog ligand can be labeled with ⁶⁸Ga (diagnostic PET) or ¹⁷⁷Lu (therapeutic beta emitter). The diagnostic RDC identifies patients who are candidates for targeted radionuclide therapy and provides baseline and post-treatment imaging to assess response.
Exclusive Analyst Observation (Q2 2025 Data): The diagnostic RDC market is characterized by the rapid expansion of PSMA-targeted imaging for prostate cancer (⁶⁸Ga-PSMA-11, ¹⁸F-DCFPyL, ¹⁸F-PSMA-1007) and SSTR-targeted imaging for neuroendocrine tumors (⁶⁸Ga-DOTATATE, ⁶⁴Cu-DOTATATE). These two applications represent approximately 50-60 percent of the diagnostic RDC market. The development of theranostic pairs (diagnostic RDC identifies patients; therapeutic RDC treats) has accelerated adoption. For prostate cancer: ⁶⁸Ga/¹⁸F-PSMA PET identifies metastatic disease; ¹⁷⁷Lu-PSMA-617 (Pluvicto, Novartis) treats. For neuroendocrine tumors: ⁶⁸Ga-DOTATATE PET identifies SSTR-expressing tumors; ¹⁷⁷Lu-DOTATATE (Lutathera, Novartis) treats. Novartis is the dominant player in both diagnostic and therapeutic RDCs, with Lutathera and Pluvicto (therapeutic) and associated diagnostic imaging agents.
3. Competitive Landscape: Novartis Dominates, with Multiple Emerging Players
Based on QYResearch 2024-2025 market data and confirmed by company annual reports, the diagnostic RDC market features Novartis as the dominant player, along with major pharmaceutical companies, Chinese biotech companies, and specialized radiopharmaceutical developers.
Global Leader: Novartis (Switzerland, Lutathera (¹⁷⁷Lu-DOTATATE) for neuroendocrine tumors, Pluvicto (¹⁷⁷Lu-PSMA-617) for prostate cancer, with companion diagnostic imaging agents; also developing other RDCs).
Major Pharmaceutical Companies: Bayer (Germany, Xofigo (²²³RaCl₂) for bone metastases, radium-223 dichloride, diagnostic imaging agents), AstraZeneca (UK, diagnostic and therapeutic RDCs), Eli Lilly (US), BMS (US), Johnson & Johnson (US).
Chinese Biotech and Pharmaceutical Companies: Bivision (China), Grand Pharmaceutical Group Limited (China), China Isotope & Radiation Corporation (CIRC, China), Yantai Dongcheng Pharmaceutical Group Co., Ltd. (China), Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (China), Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China), SmartNuclide (China), Full-Life Technologies (China), Qingdao Baheal Medical INC. (China), Yunnan Baiyao (China), TOT Biopharm International Company Limited (China), Nuoyu Pharmaceutical (China), Foshan Ruidio Medical System Co., Ltd. (China), Chengdu Yunke Pharmaceutical Co., Ltd. (China), Shandong Andike Pharmaceutical Co., Ltd. (China), Hexin (Suzhou) Pharmaceutical Technology Co., Ltd. (China), and Sinotau (China). Chinese companies are rapidly developing diagnostic and therapeutic RDCs for the China market and global markets.
4. Market Outlook 2025-2031 and Strategic Recommendations
Based on QYResearch forecast models, the global diagnostic radionuclide drug conjugates (RDCs) market will reach US$10,117 million by 2031 at a CAGR of 11.5 percent.
For nuclear medicine physicians and oncologists: Use diagnostic RDCs (⁶⁸Ga-PSMA, ¹⁸F-PSMA, ⁶⁸Ga-DOTATATE) for accurate staging of prostate cancer and neuroendocrine tumors. Use PSMA PET to select patients for ¹⁷⁷Lu-PSMA-617 therapy. Use SSTR PET to select patients for ¹⁷⁷Lu-DOTATATE therapy.
For pharmaceutical executives: Develop diagnostic RDCs as companion diagnostics for therapeutic RDCs (theranostic pairs). Invest in novel ligands (antibodies, peptides, small molecules) targeting emerging biomarkers. Establish radiopharmacies (local production of short-half-life radionuclides) to ensure supply chain reliability.
For investors: Novartis (dominant in theranostic RDCs) is positioned for continued leadership. Chinese companies (Hengrui, Kelun-Biotech, Sinotau, Full-Life) offer exposure to the rapidly growing China market. Companies with novel ligands (e.g., FAP-targeted RDCs for multiple cancer types) are positioned for above-market growth.
Key risks to monitor include supply chain constraints for radionuclides (⁶⁸Ga requires germanium-68 generators or cyclotrons; ¹⁸F requires cyclotrons), reimbursement for diagnostic RDCs (varies by country), competition from alternative imaging modalities (FDG PET, MRI, CT with contrast), and the need for specialized infrastructure (PET/CT or SPECT/CT scanners, radiopharmacies).
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
